Targeting mitochondria with clpp agonists as a novel therapeutic opportunity in breast cancer

HIGHLIGHTS

• who: Rohan Wedam and colleagues from the Health, Bethesda, MD, USA have published the research work: Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer, in the Journal: Cancers 2023, 15, 1936. of 20/03/2023
• how: The study provided the copper chelating agent tetrathiomolybdate (TM) inhibited lung metastasis and improved copper chelating agent tetrathiomolybdate (TM) inhibited lung metastasis and improved survival benefit benefit in in TNBC TNBC patients patients (NCT00195091) (NCT00195091) .
• future: Understanding the impact of ClpP agonists on immune cells and TME is needed in future research . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.